This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novo Nordisk A/S

Drug Names(s): Anti-C5aR-151, NN-8209, NNC 0151-0000-0000

Description: For the updated version of this compound, NN8210, click here.

NN8209 is a monoclonal antibody blocking the C5aR receptor.

Deal Structure: In February 2006, G2 Inflammation Pty (G2I), a subsidiary of G2 Therapies, and Novo Nordisk announced a collaboration agreement to develop, manufacture and commercialise new anti-inflammatory therapies based on G2's C5a Receptor antibodies.

The terms of the agreement include a US$6 million upfront payment and other success-basedpayments to a potential total of US$102 million, plus royalties on commercialised therapeutics. Additionally, G2I will be reimbursed by Novo Nordisk for expenses incurred under this collaboration.

Partners: G2 Therapies Limited

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug